Table 1.

Demographics and clinical and pathology characteristics of EO-LARC patients.

Variable	Whole population		Training cohort		Validation cohort		P value
	n	%	n	%	n	%
	2440		1708		732
Age
17-30	90	3.69%	59	3.45%	31	4.23%	0.35
30-40	565	23.16%	386	22.60%	179	24.45%
40-50	1785	73.16%	1263	73.95%	522	71.31%
Race
Black	192	7.87%	132	7.73%	60	8.20%	0.89
White	1910	78.28%	1341	78.51%	569	77.73%
Other	338	13.85%	235	13.76%	103	14.07%
Sex
F	1069	43.81%	737	43.15%	332	45.36%	0.32
M	1371	56.19%	971	56.85%	400	54.64%
Pathology
Adenocarcinoma	2216	90.82%	1546	90.52%	670	91.53%	0.76
Mucinous and signet ring cell carcinoma	127	5.20%	91	5.33%	36	4.92%
Others	97	3.98%	71	4.16%	26	3.55%
Grade
I	159	6.52%	107	6.26%	52	7.10%	0.83
II	1896	77.70%	1329	77.81%	567	77.46%
III	336	13.77%	236	13.82%	100	13.66%
IV	49	2.01%	36	2.11%	13	1.78%
Stages T a
T1	62	2.54%	43	2.52%	19	2.60%	0.90
T2	187	7.66%	135	7.90%	52	7.10%
T3	1907	78.16%	1334	78.10%	573	78.28%
T4	284	11.64%	196	11.48%	88	12.02%
Stages N a
N0	745	30.53%	519	30.39%	226	30.87%	0.73
N1	1174	48.11%	817	47.83%	357	48.77%
N2	521	21.35%	372	21.78%	149	20.36%
Tumor size
0-5	1180	48.36%	838	49.06%	342	46.72%	0.54
5-10	1159	47.50%	799	46.78%	360	49.18%
>10	101	4.14%	71	4.16%	30	4.10%
Number
1	2297	94.14%	1606	94.03%	691	94.40%	0.72
>1	143	5.86%	102	5.97%	41	5.60%
LNR
0	1231	50.45%	857	50.18%	374	51.09%	0.58
0-0.2	733	30.04%	509	29.80%	224	30.60%
0.2-0.4	266	10.90%	196	11.48%	70	9.56%
>0.4	210	8.61%	146	8.55%	64	8.74%
CEA
Positive	955	39.14%	664	38.88%	291	39.75%	0.68
Negative	1485	60.86%	1044	61.12%	441	60.25%
Radiation
Yes	1805	73.98%	1271	74.41%	534	72.95%	0.45
No	635	26.02%	437	25.59%	198	27.05%
Chemotherapy
Yes	2199	90.12%	1543	90.34%	656	89.62%	0.58
No	241	9.88%	165	9.66%	76	10.38%

^aAJCC (TNM) Stages: The eighth edition AJCC (TNM) staging system.